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AbstrACt
Objectives To assess predictive factors for rheumatoid 
arthritis interstitial lung disease (RA-ILD) in two early 
rheumatoid arthritis (RA) inception cohorts with a focus on 
methotrexate (MTX) exposure.
Design Multicentre prospective early RA inception cohort 
studies; the early RA study (ERAS) and the early RA 
network (ERAN).
setting Secondary care, ERAS nine centres, ERAN 23 
centres in England, Wales and Ireland.
Participants Patients with new diagnosis of RA, n=2701. 
Standardised data including demographics, drug therapies 
and clinical outcomes including the presence of RA-ILD 
were collected at baseline, within 3–6 months, at 12 
months and annually thereafter.
Primary and secondary outcome measures Primary 
outcome was the association of MTX exposure on RA-ILD 
diagnosis. Secondary outcomes were the association of 
demographic, comorbid and RA-specific factors on RA-ILD 
diagnosis and the association of MTX exposure on time to 
RA-ILD diagnosis.
results Of 92 eligible ILD cases, 39 occurred in 1578 
(2.5%) MTX exposed and 53 in 1114 (4.8%) non-MTX 
exposed cases. The primary analysis of RA-ILD cases 
only developing after any conventional synthetic disease-
modifying antirheumatic drug treatment (n=67) showed 
MTX exposure not to be associated with incident RA-ILD 
(OR 0.85, 95% CI 0.49 to 1.49, p=0.578) and a non-
significant trend for delayed ILD diagnosis (OR 0.54, 95% 
CI 0.28 to 1.06, p=0.072). In an extended analysis 
including RA-ILD cases present at RA diagnosis (n=92), 
MTX exposure was associated with a significantly reduced 
risk of incident RA-ILD (OR 0.48, 95% CI 0.3 to 0.79, 
p=0.004) and longer time to ILD diagnosis (OR 0.41, 95% 
CI 0.23 to 0.75, p=0.004). Other independent baseline 
associations with incident RA-ILD were higher age of RA 
onset, ever smoking, male gender, rheumatoid nodules 
and longer time from first RA symptom to first outpatient 
visit.
Conclusions MTX treatment was not associated with 
an increased risk of RA-ILD diagnosis. On the contrary, 
evidence suggested that MTX may delay the onset of 
ILD.
IntrODuCtIOn
Methotrexate (MTX) is now firmly estab-
lished globally as the anchor drug for the 
management of rheumatoid arthritis (RA), 
recommended for first line use, to which 
other conventional synthetic disease-mod-
ifying antirheumatic drugs (csDMARDs), 
targeted synthetic disease-modifying anti-
rheumatic drugs and biological disease-mod-
ifying antirheumatic drugs (bDMARDs) are 
generally added.1 2 In addition to an excel-
lent ability to suppress synovitis and restore 
physical function, there is compelling data 
demonstrating a beneficial effect on long-
term cardiovascular disease3 and hence resto-
ration of life expectancy to that of the normal 
population. 
A hypersensitivity pneumonitis is a rare 
adverse effect of MTX described in 0.43%,4 
generally subacute in presentation, with 
progression of characteristic symptoms over 
a period of days to weeks.5 This usually occurs 
early, within the first year of treatment, but 
strengths and limitations of this study
 ► Multicentre prospective early rheumatoid arthritis 
(RA) inception cohort study recruiting 2701 patients.
 ► Standardised data collection with up to 25-year 
follow-up.
 ► Diagnosis of rheumatoid arthritis  interstitial lung 
disease (RA-ILD) made by participating rheuma-
tology centres, or from death certification, without 
independent verification.
 ► Univariate, multivariate, time varying and time-to-
event Cox proportional hazards analyses assessed 
methotrexate  exposure, demographic and RA-
specific factors associated with RA-ILD diagnosis.
 ► High proportion of missing smoker status data from 
early RA study patients recruited from 1986 to 2001.
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has been reported up to 3 years after starting MTX.4 5 
This organ-specific hypersensitivity reaction has led to a 
creeping concern in routine practice that MTX may also 
be associated with an increased incidence or exacerba-
tion of the interstitial lung disease (ILD) that is associated 
with RA and may be a reason to withhold MTX from RA 
patients with any lung disease. RA-ILD is an uncommon 
but significant life-threatening extra-articular manifesta-
tion, clinically significant in up to 5% of patients with 
RA, with subclinical high-resolution computed tomog-
raphy (HRCT) evidence in 33% or more, a median 
survival from diagnosis of approximately 3 years, contrib-
uting to the overall excess mortality of RA.2 6–12 MTX is 
contraindicated if a patient has insufficient respiratory 
reserve to survive hypersensitivity pneumonitis. However, 
evidence is lacking that would deter initiation of MTX 
treatment in people with mild respiratory disease on 
grounds of an adverse effect on any other form of lung 
injury such as ILD. Indeed, the considerable benefits of 
MTX are such that a decision to withhold it as a treat-
ment option for RA should be reluctantly made and only 
for sound reasons.
Evidence that MTX may cause or have an adverse 
impact on RA-ILD is sparse. Meta-analysis of randomised 
controlled trials (RCTs) of MTX in RA has reported an 
increased risk of all adverse respiratory events and respi-
ratory infections but not of death due to lung disease or 
non-infectious respiratory events, with follow-up duration 
of 24–104 weeks.13 Due to inherent difficulties separating 
RA-ILD from putative MTX-related ILD, a meta-analysis 
of MTX versus placebo or active comparator agents in 
RCTs from non-malignant inflammatory disorders not 
themselves associated with ILD is of interest.14 This has 
shown no MTX-associated risk of lung disease in studies 
ranging from 16 weeks to 52 weeks follow-up. These rela-
tively short duration analyses, in patients preselected for 
RCTs, are reassuring but require substantiation from RA 
inception cohorts or patient registries with all-comers 
included and longer follow-up. Sequential lung function 
tests in cohorts of MTX-treated patients with RA followed 
prospectively for up to 5 years have shown a sequential 
decline, with inconsistent interpretation that this is in 
keeping with,15 or in excess of,16 expected age-related 
changes. Interpretation of these studies is limited by a 
lack of inclusion of non-MTX-treated control patients 
with RA. In another cohort comparing 55 MTX-treated 
with 73 non-MTX-treated patients with established RA, 
there was no adverse influence of MTX on pulmonary 
function tests over 2 years, including a subanalysis of 
those found to have largely subclinical pulmonary 
fibrosis on HRCT.17
We report the association of MTX exposure and other 
demographic and RA-specific factors with incident cases 
of RA-ILD in two large multicentre RA inception cohorts: 
the early rheumatoid arthritis study (ERAS) and the early 
rheumatoid arthritis network (ERAN), recruiting from 
1986 to 2012 with review up to 25 years.
MethODs
Patient databases
The study used data from ERAS (1986–2001) and ERAN 
(2002–2012), two multicentre early RA inception cohorts. 
ERAS recruited 1465 patients (<2 years disease duration, 
no prior csDMARD therapy) from nine district general 
hospitals in England, followed yearly for up to 25 years 
(median follow-up 10 years). ERAN recruited 1236 
patients (<3 years disease duration) from 23 centres in 
England, Wales and Ireland, followed yearly for up to 10 
years (median follow-up 6 years). All participants gave 
informed consent. STROBE reporting cohort guidelines 
have been followed (von Elm E, Altman DG, Egger M, 
Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strength-
ening the Reporting of Observational Studies in Epide-
miology (STROBE) Statement: guidelines for reporting 
observational studies).
Recruitment into ERAS and ERAN was based on 
clinician diagnosis with 70% of patients fulfilling the 
minimum ARA criteria18 for RA at baseline and 96% by 
last visit. Patients subsequently reclassified as non-RA 
were excluded from the study.
Patient and public involvement
A patient representative from the National Rheumatoid 
Arthritis Society (NRAS) was involved in the design and 
conduct of ERAN, including decisions concerning which 
RA outcomes should be collected. By consenting to 
recruitment, patients were aware that the purposes of the 
study included examining the consequences of a range of 
RA outcomes. As patients were recruited at the time of, 
or very soon after, the diagnosis of RA they had limited 
experience of the disease to determine their priorities for 
ERAS/ERAN analyses. ILD was one of many outcomes 
that patients knew were to be studied. As ILD is estab-
lished as one of the most severe complications of RA, and 
one of the leading causes of premature death, patients 
were interested in any findings that might add to our 
knowledge of this complication.
Patients were not involved in the recruitment process 
to ERAS/ERAN. Patients were not specifically involved in 
the statistical design of the analysis of ERAS/ERAN data 
on associations of factors with RA-ILD.
At recruitment, patients were informed that ‘the results 
of this study would be made available to participating 
clinicians and will be the subject of international presen-
tations and articles in peer-reviewed scientific journals’. 
Participants will not be notified of the results individu-
ally, but we will request that a summary of the findings 
be made available to all patients with RA via the patient 
newsletter of NRAS.
Clinical and laboratory measures
Information on demographic, clinical, treatment, labora-
tory and functional features was recorded in both cohorts 
at baseline, between 3 and 6 months, at 12 months and 
then once yearly on standardised case report forms 
(CRFs) as previously described.19–21 The disease activity 
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score (DAS) was calculated according to the original 
three-variable method22 in ERAS and the four-variable 
DAS28 method23 in ERAN. A transformation formula 
was used to make DAS and DAS28 comparable.24 Source 
data verification was undertaken by an experienced nurse 
practitioner at visits to each centre. Combined analysis 
of ERAS and ERAN is possible since they are consecutive 
inception cohorts with similar design, including the vari-
ables captured, timing of assessments and patient recruit-
ment. Follow-up across ERAS and ERAN was relatively 
high given the long term of both prospective studies, and 
of those not followed to death or closure, cases lost to 
follow-up for no known reason were only 13.7% overall 
(12.5% ERAS, 15% ERAN). Full details of reasons for 
discontinuation in ERAS and ERAN are shown in online 
supplementary table 1.
treatment profiles
Patients were treated according to usual care in each 
of the ERAS and ERAN centres, without specific proto-
cols, strategies or other external influences. All centres 
followed the 1992 good practice guidance outlined by 
the British Society for Rheumatology and Royal College 
of Physicians.25 Treatment details were entered onto the 
CRF at each ERAS/ERAN data collection visit. At base-
line, all patients in ERAS were csDMARD naïve and in 
ERAN 13.5% had commenced a csDMARD within a few 
weeks of first secondary care visit. In ERAS and ERAN, 
initial csDMARD use was as monotherapy with/without 
steroids in >90%, favouring sulphasalazine (SSZ) from 
1986 to 2001, with a switch to MTX monotherapy such 
that SSZ and MTX were used in equal proportions as 
first csDMARD in 2002, and thereafter in ERAN MTX 
became the most likely initial choice,20 21 this reflecting 
contemporary best practice. Combination csDMARDS 
were generally used for more severe RA and were intro-
duced at earlier time-points in the later years of ERAS 
and in 25% of those who received any csDMARDs in 
ERAN.20 21 In ERAN, the most frequently used combina-
tions of csDMARDs were MTX/SSZ, MTX/SSZ+hydroxy-
chloroquine (HCQ) and MTX/HCQ.21 Only a small 
proportion of patients received bDMARDs, which were 
available from 2002 onwards (<2% by 1 year and <10% by 
3 years).
Median time from RA symptom onset to first rheuma-
tology outpatient visit (baseline assessment) was 6 months 
in both cohorts and to first csDMARD initiation 8 months 
in ERAS and 7 months in ERAN.
ILD identification
Comorbidities including respiratory disease were entered 
on the CRF at each visit. Death certification was received 
from the National Health Service (NHS) medical research 
information service and subsequently the NHS Health 
and Social Care Information Center for all recruited 
patients 4 monthly with last data inclusion for this anal-
ysis June 2018. The diagnosis of ILD at each centre 
was according to standard practice, with confirmatory 
evidence from standard investigations including pulmo-
nary function tests, chest radiographs and HRCT scans. 
ILD was deemed to be present if the terms pulmonary 
fibrosis or ILD were listed on the CRF or the death certif-
icate using international classification of diseases 10th 
revision (ICD-10) criteria.
As the development of RA-ILD is insidious, setting a 
time of onset had to be pragmatic. In cases where ILD 
was recorded on the baseline CRF, the time of diagnosis 
was taken as synchronous with RA onset (n=25). In cases 
where the first record of ILD was on a CRF, the date of 
onset was taken as then (n=52). Where the only record 
of ILD was on the death certificate, and not on the last 
CRF, the date taken as onset of ILD was recorded as last 
CRF +1 year if the time from last CRF to death was 2 years 
or less (n=5), and recorded as last CRF +2 years if this 
interval was more than 2 years (n=10).
MtX-exposed ILD group
Patients were included in the analysis as MTX-exposed 
ILD if they were recorded on the CRF as starting MTX 
at any time prior to the first record of ILD, either on the 
CRF or the death certificate.
non-MtX-exposed ILD group
Patients were included in the analysis as non-MTX-ex-
posed ILD if they were recorded as having ILD on the CRF 
without record of prior MTX treatment. As the analysis 
was concerned with the onset of ILD, patients who started 
MTX at any time point after ILD was first recorded on 
the CRF remained in the non-exposed group, as ILD was 
first diagnosed before MTX treatment. Patients who were 
recorded as having ILD on the death certificate but not 
on the last CRF were included in the non-MTX exposed 
group if the time interval between last CRF and death 
was less than 2 years, and no MTX treatment had been 
recorded on the CRFs throughout ERAS/ERAN data 
collection. As the development of RA-ILD is slow, it was 
considered that this was too short a time for any potential 
but unknown MTX use after the last CRF to have had an 
effect had it been introduced. If this time interval was 2 
years or longer, patients were excluded from the analysis 
as they could have been exposed to MTX for the first time 
after last CRF and before the first record of ILD on the 
death certificate, and as such any potential MTX exposure 
during this time could have had an effect. Patients where 
the first record of ILD and MTX use was on the same CRF 
were considered non-MTX exposed as the maximum time 
MTX could have been used since the preceding CRF was 
1 year, and this was considered too short to have had an 
effect on the development of ILD within the same period.
statistical analysis
All analysis used statistical software Stata/IC V.15.1. The 
primary analyses included all cases of incident RA-ILD 
reported after any csDMARD exposure. An extended 
analysis was performed on the entire cohort of incident 
RA-ILD including patients where ILD was recorded at 
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the baseline visit. These additional cases had developed 
ILD either preceding or synchronously with RA and 
prior to any csDMARD use for RA. First univariate anal-
yses were performed for associations of baseline covari-
ates with RA-ILD development. Next multivariate binary 
logistic models were fitted to the data to determine inde-
pendent baseline predictors of RA-ILD. As there were 
multiple data collection points across the ERAS and 
ERAN follow-up period, multivariate time-varying analysis 
using Cox proportional hazards models were created to 
include multiple data entries for covariates with repeated 
measures. Finally, Cox regression time-to-event analysis 
was used to assess the relation between first RA symptoms 
and time of ILD diagnosis in MTX exposed and non-MTX 
exposed ILD cases and with respect to other baseline 
covariates.
A detailed description of the univariate and multivariate 
model analyses is given in online supplementary material.
resuLts
A flow chart of patient selection in shown in figure 1. 
From 2701 patients, a total of 101 cases of ILD were 
recorded (3.7%), of which 25 were present at baseline 
(25%). None of the baseline ILD cases had been treated 
with csDMARDs prior to first CRF. Nine ILD cases were 
Figure 1 Diagram showing patient selection and allocation to MTX-exposed and non-MTX-exposed groups. CRF, case 
report form; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; ILD, interstitial lung disease; MTX, 
methotrexate.
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excluded from analysis because the only record of 
ILD was on the death certificate and over 2 years had 
elapsed between this and the last CRF, during which time 
csDMARD treatment was unknown. There were 1578 
MTX-exposed cases of whom 1539 (97.5%) were not and 
39 (2.5%) were diagnosed with ILD, and 1114 non-MTX 
exposed cases of whom 1061 (95.2%) were not and 53 
(4.8%) were diagnosed with ILD. Of the 53 non-MTX-ex-
posed ILD cases, 19 (35%) were treated with MTX after 
ILD was diagnosed.
Demographic features of the ERAS and ERAN cohorts 
are shown in table 1. These were generally similar across 
both cohorts; however, there were significant differences 
in age of RA onset (older in ERAN), baseline smoking 
status (more current and ex smokers in ERAN) and MTX 
use (79% ERAN vs 41% ERAS). The prevalence of ILD was 
3.2% in ERAN and 4.2% in ERAS (n.s.). The median dose 
of MTX across both cohorts was 12.5 mg, but following 
contemporary practice, this increased with time: ERAS 
10 mg and ERAN 20 mg per week. Table 2 shows demo-
graphic features of MTX-exposed and non-MTX-exposed 
cases, where MTX-exposed patients were significantly 
more likely to have developed RA at a younger age, be in 
a higher DAS category, rheumatoid factor (RF) positive, 
nodular, male and borderline more likely to be current 
or ex-smokers. In the MTX-exposed cases, the median 
time from exposure to MTX to the first record of ILD was 
45 months (ERAS 47 and ERAN 26 months). The mean 
DAS28 score at first record of RA-ILD in MTX-exposed 
cases was 3.77 and in non-MTX-exposed cases 4.27 (t-test 
p=0.30).
As we were specifically interested in the relation of 
ILD onset to MTX exposure, the primary analysis was 
restricted to cases where ILD was only diagnosed after any 
csDMARD exposure (n=67), excluding 25 cases with ILD 
recorded at baseline. Univariate analyses of the relation 
between new diagnosis of RA-ILD and a range of binary 
and continuous variates are shown in online supple-
mentary table 2a and 2b. This shows no association of 
MTX exposure and incident RA-ILD: OR 0.96, 95% CI 
0.57 to 1.63, p=0.872. Male gender (p=0.034), RF posi-
tivity (p=0.01), ever smoking (p=0.004), rheumatoid 
nodules (p=0.005), age of RA onset (p=0.004) and base-
line erythrocyte sedimentation rate (ESR) (p=0.014) 
were all significantly associated with incident RA-ILD. 
Longer time between first RA symptoms and the first 
outpatient appointment (p=0.053), respiratory comor-
bidities (p=0.056) and minor comorbidities (p=0.053) 
were borderline significant. Patients who developed ILD 
were at RA onset a mean 5.14 years older and had a mean 
baseline ESR score of 8.64 mm/hour higher than patients 
who did not develop ILD.
Table 3 shows the covariates independently associated 
with ILD diagnosis in the best fit multivariate model. 
This confirms higher age of RA onset, ever smoking, 
RF positivity and longer time from first RA symptom to 
first OPD visit were independently associated with inci-
dent RA-ILD, and there remained no evidence that MTX 
exposure was associated with RA-ILD onset (OR=0.85, 
95% CI 0.48 to 1.49, p=0.578). Unlike univariate analysis 
in this model baseline major comorbidities (excluding 
respiratory) were protective. This group of conditions 
Table 1 Demographic features of the ERAS and ERAN cohorts
Number
Total ERAS ERAN
χ2 p value2701 1465 1236
Gender Male 893 33.1% 492 33.6% 401 32.4% 0.530
Female 1808 66.9% 973 66.4% 835 67.6%
Age of RA onset <55 1146 42.4% 659 45.0% 487 39.4% 0.013
56–64 728 27.0% 380 25.9% 348 28.2%
65+ 827 30.6% 426 29.1% 401 32.4%
Baseline Smoker status Never 995 36.8% 528 36.0% 467 37.8% <0.001
Current 594 22.0% 179 12.2% 415 33.6%
Ex-Smoker 518 19.2% 209 14.3% 309 25.0%
Other 26 1.0% 26 2.1%
Missing 568 21.0% 549 37.5% 19 1.5%
MTX exposure No 1114 41.2% 857 58.5% 257 20.8% <0.001
Yes 1578 58.4% 602 41.1% 976 79.0%
Missing 9 0.3% 6 0.4% 3 0.2%
ILD diagnosis No 2600 96.3% 1404 95.8% 1196 96.8% 0.206
Yes 101 3.7% 61 4.2% 40 3.2%
ERAN, early rheumatoid arthritis network; ERAS, early rheumatoid arthritis study; ILD, interstitial lung disease; MTX, methotrexate; RA, 
rheumatoid arthritis.
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included malignancies, cardiac disease, other non-car-
diac cardiovascular conditions (eg, hypertension and 
cerebrovascular disease), diabetes, thyroid disease, osteo-
arthritis, spinal disorders and gastrointestinal conditions 
as defined by ICD-10 criteria.
Extending the analysis to all 92 RA-ILD cases, including 
25 recorded at baseline prior to any csDMARD use, 
produced similar results on univariate analysis (see online 
supplementary table 3a, 3b) with male gender (p=0.002), 
baseline positive RF (p=0.038), ever smoking (p=0.002), 
presence of rheumatoid nodules (p=0.003), age of RA 
onset (p<0.0001) and baseline ESR (p=0.001) all associ-
ated with incident RA-ILD. MTX exposure was associated 
with a significantly reduced OR of developing ILD (O.R. 
0.51, 95% CI 0.32 to 0.79, p=0.001). Patients who devel-
oped ILD were at RA onset a mean 6.93 years older and 
had a mean baseline ESR score of 10.51 mm/hour higher 
than patients who did not develop ILD. In the multivariate 
model (table 3), higher age of RA onset, ever smoking, 
male gender, baseline rheumatoid nodules, higher base-
line ESR and longer time from first RA symptom to first 
OPD visit were independently associated with incident 
RA-ILD. MTX exposure (O.R. 0.48, 95% CI 0.3, 0.79) and 
baseline major comorbidities (excluding respiratory) 
were associated with significantly reduced odds of RA-ILD 
onset.
As there was a large number of patients in ERAS with 
missing smoking status at baseline (n=549), a sensitivity 
analysis of the primary cohort was performed by running 
the multivariate analysis in smokers, non-smokers and 
those with missing smoking status data (see online supple-
mentary table 4). This continued to show no associa-
tion between MTX use and incident RA-ILD in smokers 
(OR=1.56, 95% CI 0.74 to 3.29, p=0.240) and in those 
with missing smoking data (OR=1.35, 95% CI 0.33 to 
5.52, p=0.681), but MTX use was associated with a reduc-
tion in incident RA-ILD in non-smokers (OR=0.24, 95% 
CI 0.08 to 0.70, p=0.009).
The multivariate time-varying analysis, incorporating 
multiple data entries for covariates measured at each 
follow-up visit (eg, DAS, individual DAS components, 
health assessment questionnaire (HAQ), full details 
Table 2 Demographic features of MTX-exposed and non-MTX-exposed cases
Total
Total Non-MTX exposed MTX exposed
χ2 p value2692 1114 1578
Gender Male 1804 67.0% 721 64.7% 1083 68.6% 0.034
Female 888 33.0% 393 35.3% 495 31.4%
Age of RA 
onset
<55 1144 42.5% 436 39.1% 708 44.9% <0.001
55–64 723 26.9% 277 24.9% 446 28.3%
65+ 825 30.6% 401 36.0% 424 26.9%
Baseline 
smoking 
status
Never 991 36.8% 346 31.1% 645 40.9% 0.058
Current 594 22.1% 179 16.1% 415 26.3%
Ex-smoker 518 19.2% 172 15.4% 346 21.9%
Other 25 0.9% 2 0.2% 23 1.5%
Missing 564 21.0% 415 37.3% 149 9.4%
Baseline 
erosions
No erosions 1883 69.9% 808 72.5% 1075 68.1% 0.117
Erosions 699 26.0% 276 24.8% 423 26.8%
Missing 110 4.1% 30 2.7% 80 5.1%
Baseline RF Negative 977 36.3% 462 41.5% 515 32.6% <0.001
Positive 1633 60.7% 628 56.4% 1005 63.7%
Missing 82 3.0% 24 2.2% 58 3.7%
Baseline 
nodules
None 2515 93.4% 1057 94.9% 1458 92.4% 0.010
Nodules 177 6.6% 57 5.1% 120 7.6%
Baseline 
DAS
<1.6 31 1.2% 5 0.4% 26 1.6% <0.001
1.6–2.59 298 11.1% 163 14.6% 135 8.6%
2.6–3.2 345 12.8% 180 16.2% 165 10.5%
>3.2–4.19 543 20.2% 243 21.8% 300 19.0%
4.2–5.1 – – – – – –
>5.1 1415 52.6% 503 45.2% 912 57.8%
Missing 60 2.2% 20 1.8% 40 2.5%
DAS, disease activity; MTX, methotrexate; RA, rheumatoid arthritis.
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in online supplementary materials), resulted in similar 
covariate associations with incident RA-ILD. The best 
fit model (see online supplementary table 5) with the 
lowest Akaike information criterion score showed signif-
icant associations with age of RA onset (p=0.002), HAQ 
(p=0.007) and ESR (p=0.01) and continued to show no 
association with MTX exposure (HR 0.96, 95% CI 0.82 to 
1.12, p=0.629).
The relation between time to RA-ILD diagnosis after 
first RA symptoms in the MTX-exposed and non-MTX-ex-
posed groups is shown in figure 2 (primary analysis) and 
figure 3 (extended cohort). The MTX-exposed ILD group 
included 10 cases where RA-ILD was only recorded on the 
death certificate and a mean 6.6 (range 3–11) years had 
elapsed between this and last CRF. For these cases, the 
time of ILD diagnosis was unknown and pragmatically 
was recorded as last CRF +2 years, introducing a bias to 
earlier record of time of RA-ILD diagnosis. The primary 
analysis, excluding 25 cases with RA-ILD diagnosed at 
baseline pre-csDMARD treatment, showed higher age 
of RA onset associated with earlier RA-ILD diagnosis 
(HR 1.03, 95% CI 1.0 to 1.06, p=0.048) and a non-signif-
icant trend for longer time to RA-ILD diagnosis in MTX 
exposed cases (HR 0.54, 95% CI 0.28, 1.06, p=0.072). The 
extended cohort analysis showed a significantly longer 
time to diagnosis of RA-ILD in MTX-exposed compared 
with non-MTX-exposed cases (HR 0.41, 95% CI 0.23 to 
0.75, p=0.004) and the same effect of higher age of RA 
onset and earlier diagnosis (HR 1.03, 95% CI 1.0 to 1.06, 
p=0.028), but no influence of any of the other covariates 
independently associated with RA-ILD onset in the multi-
variate model (see table 4).
DIsCussIOn
We report an overall prevalence of RA-ILD of 3.7% 
in ERAS and ERAN, two large RA inception cohorts, 
recruiting between 1986 and 2012 with maximum 
follow-up of 25 years. These findings extend the earlier 
report of RA-ILD from the ERAS cohort alone8 and are in 
keeping with previous studies, including the UK BRILL 
network, which reported 2%–3% prevalence across its 
recruiting centres.10–12 ILD was already present at base-
line assessment in 25 patients, representing 24.7% of 
the entire ILD group, these cases developing ILD either 
before or synchronously with first joint symptoms. This is 
similar to the UK BRILL cohort where 10% developed ILD 
before joint disease and 7% synchronously,10 and consis-
tent with our earlier report from ERAS alone where ILD 
was present at baseline in 12/52 (23%) cases.8 Discrepan-
cies may reflect the method of detection as demonstrated 
by Gabbay et al9, who studied 36 patients with early RA 
and found abnormalities consistent with RA-ILD using a 
range of clinical, physiological and imaging modalities in 
58%, but this was clinically significant in only 14%.
The results of the multvariate analysis concurred with 
other studies8–11 in finding an association of incident 
RA-ILD with increasing age of RA onset, ever smoking and 
positive RF in the primary analysis and also male gender, 
baseline rheumatoid nodules and ESR on the extended 
analysis. As was found with our earlier report from ERAS 
alone,8 there was no association in the primary analysis 
between MTX exposure and incident RA-ILD, either on 
univariate or multivariate analyses. On the contrary, MTX 
exposure was associated with significantly less RA-ILD in 
the extended analysis. This concurs with the meta analyses 
Table 3 Multivariate logistic analysis showing covariates independently associated with RA-ILD development
Primary analysis, RA-
ILD onset after any 
csDMARD exposure 
(n=67) Wald test
Extended cohort, 
including RA-ILD onset 
prior to  any csDMARD 
(n=92) Wald test
OR (95% CI) P value OR (95% CI) P value 
Methotrexate exposure 0.85 (0.49 to 1.49) 0.578 0.48 (0.3 to 0.79) 0.004
Age RA onset 1.04 (1.02 to 1.06) <0.001 1.04 (1.02 to 1.06) <0.001
Smoking, ever, baseline 2.21 (1.21 to 4.03) 0.01 1.91 (1.13 to 3.25) 0.016
Male gender 1.44 (0.83 to 2.48) 0.193 1.74 (1.05 to 2.86) 0.03
RF positive, baseline 2.02 (1.07 to 3.82) 0.029 n.s.
RA nodules, baseline n.s. 2.19 (1.08 to 4.41) 0.029
Onset − OPD 1.04 (1.00 to 1.07) 0.027 1.03 (1.0 to 1.07) 0.04
Baseline major 
comorbidities*
0.62 (0.40 to 0.95) 0.027 0.67 (0.46 to 0.98) 0.037
Baseline ESR - n.s. 1.01 (1.0 to 1.02) 0.047
Onset − OPD: time from first RA symptoms to first hospital out patient appointment.
Note: variables not reported did not reach statistical significance in the respective models.
*Excluding respiratory.
csDMARD, conventional synthetic disease-modifying antirheumatic drugs; RA-ILD, rheumatoid arthritis interstitial lung disease; RF, 
rheumatoid factor.
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of RCTs by Conway et al, who found no association of MTX 
use and ILD in RA and non-RA inflammatory diseases,13 14 
with the prospective 2-year study reported by Dawson et 
al of 128 RA patients with established disease,17 and a 
recent report from the same group in 106 patients with 
RA commencing MTX and followed for 10 years.26 The 
implication is to be especially vigilant for the develop-
ment of RA-ILD in male patients who are RF positive, have 
nodules, a history of ever smoking and older age of RA 
diagnosis. MTX should only be witheld from RA patients 
with insufficient respiratory reserve to make it unlikely 
that they would survive hypersensitivity pneumonitis. Our 
findings refute concerns among clinicians that there is 
an association with MTX exposure and RA-ILD onset and 
provide no justification to delay or deny patients MTX for 
fear of inducing RA-ILD while seeking specialist opinions 
or further investigations of potential respiratory disease 
or other comorbid features. Such delays are likely to 
worsen RA outcomes by unnecessarily denying patients 
the anchor csDMARD for this disease. Reassurance of 
the benign effect of MTX on established RA-ILD comes 
from no association found between MTX and hospital-
ised severe ILD episodes in USA National Databank for 
Rheumatic Diseases27 and mortality from ILD in the USA 
Veterans Affairs Rheumatoid Arthritis Registry.28 Further-
more, a retrospective analysis of prognostic factors in 78 
cases of RA-ILD, where MTX was specifically used as a 
therapeutic agent in 67%, found this to be strongly asso-
ciated with survival.29
Of interest is the finding of a significant association 
between incident RA-ILD and increased time from RA 
symptom onset to first outpatient visit on multivariate 
analysis in both the primary analysis and extended cohort. 
Both of the other two measures of time to secondary care 
intervention, first RA symptom to first csDMARD and first 
outpatient appointment to first csDMARD, were consis-
tent with this association, with the interval being a mean 
3.42 and 2.56 months longer, respectively, in patients 
who subsequently developed ILD in the primary anal-
ysis. This is perhaps supportive of the so-called window of 
opportunity whereby a delay in treatment leads to worse 
outcomes. The explanation for the protective effect of 
Figure 2 Cox proportional time-to-event analysis showing time of onset of RA-ILD from first joint symptoms of RA in MTX-
exposed and non-MTX-exposed groups. Primary analysis: cases with RA-ILD first recorded after any csDMARD exposure 
(n=67). csDMARD, conventional synthetic disease-modifying antirheumatic drug; MTX, methotrexate; RA-ILD, rheumatoid 
arthritis interstitial lung disease.
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Figure 3 Cox proportional time-to-event analysis showing time of onset of RA-ILD from first joint symptoms of RA in MTX-
exposed and non-MTX-exposed groups. Extended cohort: all cases with RA-ILD including those diagnosed at baseline before 
any csDMARD exposure (n=92). csDMARD, conventional synthetic disease-modifying antirheumatic drug; MTX, methotrexate; 
RA-ILD, rheumatoid arthritis interstitial lung disease. 
Table 4 Cox regression time-to-event analysis showing associations of methotrexate exposure and baseline covariates with 
time from RA first symptoms to RA-ILD onset
Primary analysis, RA-ILD 
onset after any csDMARD 
exposure (n=67)
Extended cohort, including 
RA-ILD onset pre any 
csDMARD (n=92)
P value HR (95% CI) P value  HR (95% CI) 
Methotrexate exposure 0.54 (0.28 to 1.06) 0.072 0.41 (0.23 to 0.75) 0.004
Age RA onset 1.03 (1 to 1.06) 0.048 1.03 (1 to 1.06) 0.028
Smoking, ever, baseline 1.09 (0.52 to 2.26) 0.817 1.16 (0.61 to 2.22) 0.654
Male gender 1.02 (0.51 to 2.03) 0.966 0.85 (0.47 to 1.54) 0.587
RF positive, baseline 0.96 (0.69 to 1.32) 0.799 1.08 (0.85 to 1.38) 0.512
Onset – OPD 0.98 (0.94 to 1.03) 0.424 0.98 (0.94 to 1.02) 0.276
Baseline major 
comorbidities*
1.26 (0.69 to 2.28) 0.452 1.09 (0.63 to 1.9) 0.762
Onset – OPD: time from first RA symptoms to first hospital outpatient appointment.
*Excluding respiratory.
csDMARD, conventional synthetic  disease-modifying antirheumatic drug; RA-ILD, rheumatoid arthritis interstitial lung disease; RF, 
rheumatoid factor.
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baseline major comorbidities (excluding respiratory) 
on incident RA-ILD in both the primary analysis and the 
extended cohort is not immediately apparent. We specu-
late that this might be explained by treatment differences, 
for example, as malignancy was one of the more common 
major comorbidities, previous cancer therapies may have 
afforded immunosuppressive effects.
Interestingly, there was a trend for ILD to be less preva-
lent in the later 2002–2012 ERAN cohort (3.2%) than the 
1986–2001 ERAS cohort (4.2%) based on a sample size of 
101 cases. This is in contrast to a report of increasing prev-
alence over time among US veterans from 1985 to 2006, 
assumed due to increased awareness and investigation of 
respiratory symptoms coupled with increased survival.30 31 
The reason for an apparent decrease in incident RA-ILD 
in ERAN is unclear; however, it is noteworthy that this was 
seen despite a significant increase in two exacerbating 
factors, age of RA onset and current smoking, in ERAN 
compared with ERAS. MTX use was higher in ERAN, 
raising the intriguing question whether MTX may have 
had a protective effect on ILD development despite the 
higher risk factors in ERAN. This is supported by the 
time-to-event analysis where MTX exposure was associ-
ated with a significantly longer time to RA-ILD onset in 
the extended analysis and a trend supporting this in the 
primary analysis with fewer cases. A protective effect of 
MTX could have been due to better overall RA disease 
control than in the non-MTX-exposed group, where the 
majority received SSZ and a minority HCQ or leflun-
omide.20 21 This is supported by the lower DAS28 score 
at first record of ILD in MTX-exposed compared with 
non-MTX-exposed cases, although the difference was not 
significant. A positive influence of MTX is also supported 
by Rojas-Serrano et al29, who found a strong survival effect 
of MTX on established RA-ILD. Further evidence for an 
association between RA-ILD and worse disease control 
comes from the USA Rochester cohort followed up to 
2006, where parameters indicative of more severe RA, 
such as ESR, nodules and destructive joint changes were 
associated with ILD.11 Similarly, in the UK BRILL cohort, 
anti-cyclic citrullinated peptide  (anti-CCP) antibodies 
showed the strongest association with ILD,10 this being 
a recognised marker of disease severity. Unfortunately, 
there were insufficient numbers of ERAS/ERAN patients 
with baseline anti-CCP to assess the impact of this on ILD. 
However, we found higher baseline ESR to have a signif-
icant association with incident RA-ILD on univariate and 
multivariate analysis, this being mean 8.64 mm Hg higher 
in patients who developed ILD in the primary analysis. 
Although the ERAS/ERAN cohorts were not designed 
to compare treatment effects, the conclusion from our 
findings is that MTX has no association with the devel-
opment of RA-ILD and may lead to a delayed onset and 
lower incidence of RA-ILD perhaps as a consequence of 
better overall RA disease control or specific lung-medi-
ated immune suppression.
strengths and limitations of this study
The strength of this study is inherent in the nature of 
ERAS and ERAN, two real-world large inception early 
RA cohorts, recruiting all-comers, treated according to 
contemporary best practice, with the rigour of regular 
standardised assessments and data collection allowing 
data to be pooled and analysed collectively. In contrast to 
RCTs, the data from ERAS and ERAN are not restricted to 
defined RA populations with strict inclusion and exclusion 
criteria, nor to treatment strategies confined by protocol. 
ERAS and ERAN are also unique in size recruiting 2701 
patients compared for example to 582 in the Rochester 
cohort,11 and in the long duration of follow-up, adding 
to the strength of these analyses. The primary analysis of 
67 incident RA-ILD cases allowed us to focus on the asso-
ciation with MTX by excluding cases with ILD occurring 
before any csDMARD use.
It is possible that treatment decisions, being at the discre-
tion of each centre, were influenced by channelling bias, 
whereby patients perceived to be at higher risk of RA-ILD, 
such as those with lung disease, might have been excluded 
from MTX exposure. However, there was no difference in 
MTX exposure between those with and without baseline 
respiratory comorbidities, and MTX-exposed patients 
were more likely to be current and ex-smokers (table 2) so 
this seems unlikely. We have assumed that all cases of ILD 
occurring at baseline were RA related. This would seem 
the most likely aetiology, especially in those where the 
onset was synchronous with joint disease, but potentially 
other causes might have explained ILD. As ERAS closed 
to follow-up in 2011 and ERAN in 2013, it is possible 
that new cases of RA-ILD were missed after last CRF and 
predeath. However, we have reported RA-ILD survival to 
be a median of 3 years (5-year survival 38.8%) in ERAS8 
and with last CRF 2011–2013 and latest death certification 
reports included up to June 2018, it is not likely that many 
new cases in this period have been missed. Nonetheless, 
we have had to exclude nine RA-ILD cases from analysis, 
as we could not confirm that they remained non-MTX 
exposed, given lack of follow-up data between last CRF +2 
years and death when RA-ILD was first notified. Our inci-
dent RA-ILD cases available for analysis are therefore 
lower than reality. A further limitation of the data is the 
lack of external confirmation of ILD case verification; 
this being dependent on the reporting of ILD by each 
centre on the CRF, or the doctor completing the death 
certificate. While the diagnosis of ILD is strongly influ-
enced by investigations, with incrementally increasing 
detection from clinical signs to pulmonary function tests 
and HRCT images, and much subclinical disease being 
present,5 9 we believe that the specific diagnostic features 
of ILD and thoroughness of clinical work up by recruiting 
centres were sufficient to have confidence in the accu-
racy of ILD reporting. Furthermore, credibility of ILD 
reporting in ERAS/ERAN is gained from the prevalence 
being in keeping with other cohorts where it was possible 
to independently verify the diagnosis for each case.9–12 
Another limitation is that smoking status was missing in 
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a large proportion of ERAS patients, because its impor-
tance was not appreciated at the time data were collected 
in the 1980s. However, the sensitivity analysis, running the 
multivariate model stratified by smoking status at baseline 
did not change the lack of association between MTX and 
RA-ILD onset.
In conclusion, we report a prevalence of RA-ILD in the 
ERAS/ERAN cohorts of 3.7% with independent signif-
icant incident associations in line with other studies, 
namely older age of RA onset, ever smoking, nodules, 
RF positivity, male gender and high ESR. We also show a 
significant association of incident RA-ILD with a longer 
time from first RA symptoms to secondary care inter-
vention supporting the ‘window of opportunity’. We 
have found no association between MTX treatment and 
incident RA-ILD and on the contrary provide evidence 
suggestive that MTX-exposed patients with RA may have 
a delayed onset of ILD. There seems no reason to confuse 
the association of MTX and hypersensitivity pneumo-
nitis with the onset of RA-ILD. Assuming baseline lung 
function is sufficient to withstand an episode of hyper-
sensitivity pneumonitis, there are no other respiratory 
contraindications to the use of this very effective ‘anchor’ 
csDMARD in patients with RA.
Key messages
 ► In early rheumatoid arthritis study/early rheumatoid 
arthritis network, incident rheumatoid arthritis inter-
stitial lung disease (RA-ILD) is significantly associated 
with older age of rheumatoid arthritis (RA) onset, 
ever smoking, nodules, rheumatoid factor positivity, 
male gender, ESR and a longer time from first RA 
symptoms to first secondary care visit.
 ► There is no association between incident RA-ILD and 
methotrexate (MTX) treatment.
 ► MTX may have a protective role in delaying the onset 
of RA-ILD.
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